Hyperion Therapeutics Announces First Quarter 2013 Operating Results
5/10/2013 9:29:52 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SOUTH SAN FRANCISCO, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported the first commercial net sales of RAVICTI™ (glycerol phenylbutyrate) Oral Liquid as part of its financial operating results for the first quarter ended March 31, 2013.
Help employers find you! Check out all the jobs and post your resume.